Kornimate/medical-research-clean huggingface dataset:
study of amg 706 in subjects with advanced gastrointestinal stromal tumors (gists)

Conditions: Gastrointestinal Cancer

Summary: this study will determine the safety and effectiveness of amg 706 in patients with advanced gist.

expanded access: amgen provides expanded access for this clinical trial. contact the amgen call center (866-572-6436) for more information.

Eligibility criteria:
inclusion criteria * age ≥ 18 years; * disease progression per response evaluation criteria in solid tumors (recist) during previous treatment with imatinib mesylate at least 600 mg daily for at least 8 weeks, as per two independently assessed prestudy computerized tomography (ct) scans; * presence of at least one measurable (per recist) * progressing tumor lesion not previously treated with radiotherapy or embolization and evaluable by ct scan or magnetic resonance imaging (mri); * karnofsky performance status ≥ 60; * imatinib treatment terminated at least 7 days before study day 1; * adequate hepatic, renal, and cardiac function. exclusion criteria: * prior malignancy (other than gist, in situ cervical cancer, or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for ≥ 3 years; cardiac disease including myocardial infarction, unstable angina, and congestive heart failure (new york heart association class \> ii), * uncontrolled hypertension (systolic \> 145 mmhg or diastolic \> 85 mmhg), * history of arterial thrombosis or deep vein thrombosis (including pulmonary embolus) within 1 year of study day 1; * absolute neutrophil count \< 1.5x109/l, platelet count \< 100x109/l, hemoglobin \< 9.0 g/dl; * prior treatment with motesanib diphosphate or other kit (except imatinib) or vegf inhibitors. * the study was approved by the institutional review board of each participating institution, and all patients provided written informed consent before any study-related procedures were performed.

Keywords: gist
exploring the effectiveness of sensor-based balance training on patient outcome measures

Conditions: Diabetes; Cancer; Multiple Sclerosis; Arthritis; Parkinson's Disease; Cognitive Disorders; Brain Injury; Stroke

Summary: explore the benefit of the game-based virtual reality system in improving lower extremity kinematics and balance in patients suffering from disease/disorders including diabetes, cancer, multiple sclerosis, arthritis, parkinson's disease, cognitive disorders, brain injury, stroke or frailty. a four to six weeks of training with 2 training session/week will be provided.

individuals suffering from certain disorders/diseases including diabetes, arthritis, cancer, osteoarthritis, stroke, parkinson's disease, cognitive impairment or brain injury are more likely to experience a fall or a fall-related injury than healthy individuals during to impaired postural stability or diminished joint perception. under certain circumstance they may also experience pain, depression, anxiety, and a decreased quality of life. the investigators' research has been designed to provide exercise training using non-invasive body-worn sensors (similar to those used in an iphone®) to provide real-time visual information about joint motion in a virtual environment. these sensors will be worn using a vest, t-shirt or elastic band. the investigators will, 1) assess changes in participant's perception of lower extremity position while they perform these exercises; 2) motivate and guide simple exercise performance in the clinic/home, using an interactive game-like scheme; and 3) assess changes in participant's postural stability and gait as a result of provided exercise training. the information gathered will provide new understanding about more helpful rehabilitation strategies that improve postural stability in patient population.

Eligibility criteria:
inclusion criteria: diagnosis of: * diabetes * cancer * multiple sclerosis * arthritis * parkinson's disease * cognitive disorders * brain injury * frailty * stroke exclusion criteria: * conditions not related to specific disorders affecting balance and gait

Keywords: virtual reality sensor-based balance training gait balance
using multimodal prehabilitation to improve outcomes for frail patients undergoing resection of colorectal cancer

Conditions: Colorectal Neoplasms

Summary: the purpose of this study is to determine if a program of physical activity, nutritional supplements and relaxation techniques is effective at decreasing post operative complications in frail colorectal cancer patients undergoing resection.


Eligibility criteria:
inclusion criteria: * colorectal cancer patient undergoing resection * frail or intermediately frail patients (fried score 2 and above) exclusion criteria: * unable to communicate in french or english * premorbid conditions contraindicating physical exercise (dementia, parkinson disease, previous stroke with paresis, taking carbidopa/levodopa, donepezil or antidepressants)

Keywords: postoperative complications perioperative care colorectal surgery frail elderly
a pilot study of daptomycin for antimicrobial prophylaxis

Conditions: Antimicrobial Prophylaxis

Summary: the goals of the study are to evaluate the feasibility of using daptomycin as a prophylactic antimicrobial agent in patients undergoing cardiac surgery, to determine the rates of surgical site infection, and to evaluate the occurrence of adverse events.


Eligibility criteria:
inclusion criteria: patients will be eligible for inclusion in the study if they meet the following criteria: 1. provide signed and dated informed consent and are willing to receive the study medication 2. age ≥ 18 years of age 3. if a female of childbearing potential is willing to practice at least one method of birth control during treatment and for at least 28 days after treatment with study medication: 1. barrier methods of birth control (e.g., condoms, diaphragms together with spermicidal foam or gel, or presence of iud) or 2. surgical sterilization, approved hormonal contraceptives (such as birth control pills, depo-provera, or lupron depot), or iud are all acceptable. * rhythm, temperature, and verbal promise of abstinence are not acceptable methods of birth control. 4. if a female of childbearing potential, serum hcg negative within 24 hours of scheduled surgery. 5. planned cardiac surgery procedures meeting current duke criteria to receive anti-microbial prophylaxis active against mrsa: a. patients will meet at least one of the following criteria which are the same as for prophylaxis with vancomycin: i. preoperative hospitalization \> 48 hours ii. transfer to duke from outside facility iii. previous history of mrsa iv. any patient deemed to be high risk for mrsa by the attending surgeon, due to a complicated past medical and/or surgical history exclusion criteria: patients who satisfy any of the following are not eligible for study enrollment. 1. hypersensitivity to daptomycin 2. inability to receive standard prophylaxis agents (cefuroxime and rifampin) for any reason 3. staphylococcal bacteremia at the time of enrollment 4. diagnosis of s. aureus or coagulase negative staphylococcus pacemaker/defibrillator infection within the preceding 18 months 5. patient is undergoing emergency cabg 6. weight \>150 kg or \<50kg 7. patients considered unlikely to survive at least 7 days due to underlying illness. 8. patients with creatinine clearance (clcr) \< 30ml/min (calculated using the cockcroft-gault equation using actual body weight) 9. severe neutropenia (absolute neutrophil count \<0.500x103 /µl) 10. pregnant, nursing or lactating women (if patient is still of childbearing potential, a negative serum pregnancy test will be confirmed) 11. patients considered unlikely to comply with study procedures or to return for the scheduled post treatment evaluation 12. any other condition that in the opinion of an investigator, would confound or interfere with evaluation of safety or efficacy of the investigational medication, or prevent compliance with the study protocol

Keywords: mrsa increased risk for infection
acute hiv infection observational study

Conditions: HIV Infections

Summary: the purpose of this study is to collect data and body fluid samples from people with acute or established hiv infection and from hiv uninfected people. data from this study will be used to better understand properties of hiv, including hiv transmission and the differences between acute and established hiv infections.

previous studies have identified strategies for the large-scale identification of acute hiv infections. one system using such strategies has already been implemented in north carolina, and this system will be used in this study run by the center of hiv/aids vaccine immunology (chavi). this study will collect data on the mechanism of hiv transmission and the genetic, biologic, antigenic, and structural characteristics of the virus. the study will enroll hiv infected people with acute hiv infection and their sexual partners, people with established hiv infection, and hiv uninfected people. this study will last 96 weeks. group 1 participants will be people with acute hiv infection. these participants will have 15 study visits; some visits will include a physical exam and medical history. group 1 will also be asked to complete a sexual behavioral assessment at study entry and every 12 weeks thereafter. group 2 participants will be people with established hiv infection. group 3 participants will be hiv uninfected people. groups 2 and 3 will have 10 study visits; some visits will include a physical exam and medical history. groups 2 and 3 will also be asked to complete a sexual behavioral assessment at study entry, every 12 weeks until week 72, and week 96. group 3 will undergo hiv testing at each visit and will receive pre- and post-test counseling. at each visit, participants will undergo hiv safe sex counseling and will update their locator information. blood, genital secretion, and breast milk collection will also occur at each visit.

Eligibility criteria:
inclusion criteria for all participants: * willing to receive hiv test results * willing to provide updated locator information during the study inclusion criteria for group 1: * acute hiv infection or sexual partner of a group 1 participant with acute hiv infection inclusion criteria for group 2: * established hiv infection (positive hiv antibody test and positive hiv western blot) inclusion criteria for group 3: * hiv uninfected exclusion criteria for all participants: * plan to relocate out of the area during the study or have a job or other obligations that may require long absences from the area * currently on antiretroviral therapy. women who previously took antiretroviral therapy for the prevention of mother-to-child transmission of hiv are not excluded. * any other condition that, in the opinion of the investigator, may interfere with the study

Keywords: acute infection
dermacyd ph_detinback tangerine mix (lactic acid)- compatibility

Conditions: Hygiene

Summary: the purpose of this study is to demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product dermacyd phdetinback tangerine mix (lactic acid).


Eligibility criteria:
inclusion criteria: * age between 18 and 60 years old; * phototype skin i,ii, iii e iv; * integral skin test in the region; * willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion; exclusion criteria: * lactation or gestation; * personnel history of atopy; * history of sensitivity or irritation for topic products; * active cutaneous disease; * use of new drugs or cosmetics during the study;
characterizing late-season influenza vaccine responses to compare the 2023 and 2024 vaccine formulations

Conditions: Influenza A

Summary: every 1-2 years, the seasonal influenza vaccine composition changes to include updated viruses, yet the precise effects of updating the vaccine remain understudied. since the vaccine formulation for each season (with a season defined as starting in july and ending the following june) expires on june 30, vaccine formulations cannot be compared head-to-head. thus, the 2023 and 2024 vaccines have only been compared by analyzing people given the former vaccine in the fall of 2023 and people given the latter vaccine in the fall of 2024, and baseline repertoires may have greatly changed over the course of that year. to that end, the investigators will vaccinate a cohort with the 2023 influenza vaccine between may-june 2024, in order to compare responses between individuals receiving the 2023 vaccine last fall, the 2023 vaccine late in the season (this cohort), and the 2024 vaccine next fall. the investigators will further assess whether the late-season 2023 vaccine primed this cohort to respond better to the standard 2024 vaccine with standard timing (vaccine administered around september-october).


Eligibility criteria:
inclusion criteria: * be between 18-64 years of age * males or non-pregnant, non-nursing females * weigh at least 85 pounds for whole blood draw * ability to provide signed informed consent * subjects must plan to receive the intramuscular influenza vaccine at the la jolla institute for immunology exclusion criteria: * received an influenza vaccine in the past year * infection with human immunodeficiency virus, hepatitis b virus, or hepatitis c virus * history of certain anemias * presence of significant cardiovascular disease, systemic diseases including, but not limited to, diabetes which is not controlled, renal disease, liver disease, malignancy, infection, or blood clotting disorder * inability to provide informed consent * recent whole blood donation within 56 days or leukapheresis within 112 days * children (under 18 years of age), elderly (65 years of age or older), pregnant or nursing females * individuals with egg allergies * has ever had guillain-barré syndrome

Keywords: influenza vaccine immune response
use of mobile technology for intensive training in medication management

Conditions: Sickle Cell Disease; Thalassemia

Summary: purpose: assess whether intensive training with education and daily remote monitoring with provider involvement has a lasting positive impact on adherence to medication management. the study will seek to enroll 25 subjects with sickle cell disease or thalassemia, and less than 100% compliance for taking iron chelators in the previous three month prior to participation in the study. subjects will be asked to monitor their daily iron chelator administration by taking a video recording of preparing it and ingesting at least one sip. subjects will also use a medication log to record daily administration of medication, and meet with study staff monthly for educational activities. the data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management. mean percent adherence in the pre-study periods and each of the study periods will be analyzed and compared.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of sickle cell or thalassemia * history of iron overload exclusion criteria: * none

Keywords: sickle cell thalassemia adherence
application of a new type of whole blood coagulation time measurement in evaluating the hypercoagulable state of malignant tumors

Conditions: Neoplasm Metastasis; Blood Coagulation Disorder With Shortened Coagulation Time (Disorder); Venous Thromboembolism

Summary: malignant tumors are closely related to deep vein thrombosis, pulmonary embolism and other diseases. tumor patients usually have a hypercoagulable state (hcs) in their blood, and the proportion of thrombosis caused by hcs is more than 10 times that of non tumor patients. conventional clinical testing methods such as coagulation function, blood routine, and thromboelastography are difficult to directly evaluate the hypercoagulable state of tumor patients. in addition, the widely used khorana score and caprini score systems in clinical practice need to be improved in accurately reflecting the hypercoagulable state of tumor patients. our team has established a complete new coagulation time measurement system, including general clotting time (gct), platelet rich plasma clotting time (prp-ct), and platelet poor plasma clotting time (ppp-ct), which may be a new and accurate method for evaluating tumor hypercoagulability. the gct study aims to evaluate: 1. the time of gct, prp-ct, and ppp-ct for malignant tumors is shorter than that of normal individuals, and some patients are in a hypercoagulable state; 2. the shortened time of gct, prp-ct, and ppp-ct may be associated with future thrombosis; 3. evaluating the relationship between shortened gct system time and overall tumor survival therefore, the gct system evaluation may identify patients who are truly in a hypercoagulable state, providing monitoring indicators for subsequent anticoagulation; it can also be evaluated whether gct time can reflect the prognosis of tumor patients.


Eligibility criteria:
inclusion criteria: 1. voluntarily participate and sign an informed consent form; 2. age ≥ 18 years old 3. expected survival time\>6 months; 4. patients diagnosed with malignant tumors for the first time or progressing during treatment; 5. solid malignant tumors with clear pathological diagnosis; 6. ecog physical fitness score ≤ 2 points exclusion criteria: 1. patients with known venous thrombosis (including upper and lower limb venous thrombosis, pulmonary embolism, visceral venous thrombosis, etc.); 2. patients who have received long-term treatment with warfarin, rivaroxaban, and low-molecular-weight heparin (except aspirin, hydrogen clopidogrel, etc.); 3. patients with active infections and sepsis; 4. hematology tumor (except lymphoma); 5. patients who undergo any major surgical treatment within 28 days prior to enrollment;

Keywords: neoplasm metastasis blood coagulation disorder venous thromboembolism
safety and efficacy study of adjunctive antiplatelet therapy prior to primary pci in patients with stemi

Conditions: Myocardial Infarction

Summary: safety and efficacy of adjunctive antiplatelet therapy prior to primary percutaneous intervention (pci) in patients with st-elevation myocardial infarction (stemi)

patients with stemi who are to undergo primary pci will be randomized to an intravenous (iv) bolus of placebo vs. prt060128 prior to angiography.

Eligibility criteria:
inclusion criteria: * persistent st elevation ≥ 1mm (≥ 0.1mv) in two contiguous limb leads or ≥ 2 mm (≥ 0.2mv) in two contiguous precordial leads, and chest pain ≥ 20 minutes with onset within 6 hours of hospital presentation. exclusion criteria: * cardiogenic shock (systolic blood pressure \< 90 mm hg requiring vasopressor or hemodynamic support) * uncontrolled hypertension defined as any measured systolic blood pressure (sbp) \> 180 mm hg or diastolic blood pressure (dbp) ≥ 110 mm hg after the time -- history or symptoms of a congenital or acquired bleeding disorder or vascular malformation. * recent gastrointestinal bleeding within the last 30 days. * known thrombocytopenia (platelet count \< 100,000/mm3). * any treatment with a fibrinolytic agent within the last 7 days.

Keywords: stemi acs
the effectiveness yoga@work among office workers with chronic nonspecific neck pain (cnnp)

Conditions: Chronic Non-Specific Neck Pain

Summary: chronic nonspecific neck pain (cnnp) is a public health issues with a 50% life prevalence. cnnp is a leading cause of disability which contributes to higher costs due to loss of productivity, disability, and increased absenteeism from work. yoga has been found effective managing neck pain but there has been no study at work setting for chronic non-specific neck pain. to determine the effectiveness of yoga@work program for chronic non specific neck pain among office workers, present randomised controlled trial was undertaken.


Eligibility criteria:
inclusion criteria: * participants who gave written informed consent * having neck pain for more than 3 month exclusion criteria: * systematic disorder * neck or spine injuries * recent surgery
biomarkers and prediction of tigecycline induced coagulation dysfunction

Conditions: Blood Coagulation Disorder

Summary: this study is to screen out the biomarkers and establish the model to predict coagulation dysfunction induced tigecycline

the critically ill patients treated with tigecycline in in tensive care unit will be recruited and divided into tigecycline-induced coagulation dysfunction group and non-coagulation dysfunction group. the multi-omics will be used to screen out biomarkers for early prediction of coagulation dysfunction caused by tigecycline. afterwards, machine learning methods will be adopted to establish the the early prediction model of tigecycline-induced coagulation dysfunction.

Eligibility criteria:
inclusion criteria: * inpatients receiving tigecycline treatment in the affiliated nanjing drum tower hospital of nanjing university medical school * intravenous tigecycline ≥ 3 days * monitoring the plasma concentration of tigecycline exclusion criteria: * missing clinical data

Keywords: tigecycline blood coagulation disorder multi-omics machine learning techbology
evaluation of some risk factors associated with colorectal cancer

Conditions: Colorectal Neoplasms

Summary: 1. evaluation of some risk factors (e.g. smoking, heavy metal exposure, and organophosphorus exposure) on crc. 2. estimation of kras and braf genes mutations associated with crc. 3. association between different risk factors and gene mutations on different types of crc.

* colorectal cancer (crc) ranks as the third most common cancer globally and second in terms of mortality (bray et al., 2018). crc is the 7th commonest cancer in egypt, representing 3.47% of male cancers and 3% of female cancers (metwally et al.,2018). * studies have provided that rising crc rates are associated with increased alcohol use, physical inactivity, high intake of fat, red and processed meat, and processed foods; and low intake of fiber (zhou and rifkin, 2021). * smoking is an established risk factor for colorectal adenomas as well as crc incidence and mortality, which suggests that it may affect the prognosis of crc patients as well (walter et al., 2014). * heavy metals are natural components of the earth's crust, which, if released into the environment, can persist for many years (wu et al., 2016). the most toxic elements are arsenic, cadmium, chromium, copper, mercury, and lead with the majority of them being classified as certainly or probably carcinogenic (forte et al., 2020). * pesticides that are applied to farms can remain in the environment for longer than intended (sjerps et al., 2019). pesticides increase the risk of cancer through a variety of mechanisms including genotoxicity, epigenetic effects, hormonal action, and immunotoxicity (lyons and watterson, 2010). * of the key genes of crc, kras mutations are the most widely known, as they are mainly localized in codons 12 and 13, which were among the first linked to the pathogenesis of colon cancer (kudryavtseva et al., 2016). braf is an oncogene located on chromosome 7 for which gain of function mutations in multiple solid tumors, such as colon cancer (frisone et al., 2020).

Eligibility criteria:
inclusion criteria: - 1. patients who are recently diagnosed with crc based on clinical and pathological examinations. 2. control subjects will be crc-free, based on the clinical history and physical examination. exclusion criteria: 1 - patient refuses to be enrolled in the study. 2. subjects with cancer metastasized from other tissues to the colon. (colon is the site of metastasis)